Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT05575440
Status
Recruiting
Apply to this trial

Conditions

  • Differentiated Thyroid Gland Carcinoma
  • Thyroid Gland Follicular Carcinoma
  • Thyroid Gland Papillary Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Computed Tomography — PROCEDURE
    Undergo a PET/CT scan
  • Fluorine F 18 Tetrafluoroborate — RADIATION
    Given IV
  • Positron Emission Tomography — PROCEDURE
    Undergo a PET/CT scan
  • Survey Administration — OTHER
    Ancillary studies

Study Details

This phase II study evaluates F-18 tetrafluoroborate (18F-TFB) PET/CT scan in patients with differentiated thyroid cancer. Diagnostic imaging is necessary for planning treatment, monitoring therapy response, and identifying sites of recurrent or metastatic disease in differentiated thyroid cancer. 18F-TFB PET/CT may accurately detect recurrent and metastatic thyroid cancer lesions, with the potential to provide information for patient management that is better than the current standard of care imaging practices.

Key Dates

Start date
Apr 22, 2022
Status verified
Feb 2026
Primary completion
May 1, 2028
Completion
May 1, 2028

Study Design

Enrollment
24 participants (estimated)

Arms

  • Arm: Observational (18F-TFB PET/CT)
    Patients receive fluorine F18 tetrafluoroborate IV and undergo PET/CT scan on study.

Primary Outcome Measure

Descriptive summaries of detected lesions [ Time Frame: Up to 2 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo Clinic in RochesterRochesterMinnesota55905
Clinical Trials Referral Office
[email protected]
855-776-0015
Stephen M. Broski, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, MN

By research site
Mayo Clinic in Rochester· Rochester, MN

Related Studies